Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
University of Florida
Emory University
Children's Oncology Group
Novartis
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Hospital Los Angeles
Baylor College of Medicine
St. Jude Children's Research Hospital
Children's Oncology Group
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Hoffmann-La Roche
Children's Oncology Group